Business Context and Reporting Period
This Form 8-K is a current report filed by Sonus Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in metadata, but identified as Sonus in the filing text) on January 11, 2008. The report discloses the execution of new Severance/Change in Control Agreements with two key executives.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements.
Material Changes
On January 11, 2008, the Company entered into new agreements with:
- Michael A. Martino (Chief Executive Officer): Amends and restates his 2003 Change in Control Agreement.
- Alan Fuhrman (Senior Vice President and Chief Financial Officer): Amends and restates his 2004 Change in Control Agreement.
These agreements define severance benefits triggered by voluntary termination for "good reason," involuntary termination without cause, or a change in control.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, market outlook, or general management commentary regarding business operations. The primary disclosure details the financial terms of the executive agreements:
- Immediate Payments: Accrued/unpaid base salary and declared but unpaid deferred bonuses.
- Severance Multipliers (upon execution of release):
- Mr. Martino: 2.99 times the highest annual base salary paid in the 12 months prior to termination.
- Mr. Fuhrman: 1.0 times the highest annual base salary paid in the 12 months prior to termination.
- Benefits: Twelve months of COBRA health insurance continuation and other non-cash health/welfare benefits.
Investor Verification Checklist
- Verify the exact annual base salaries for Mr. Martino and Mr. Fuhrman to calculate potential severance liabilities.
- Review the full text of Exhibit 10.1 and Exhibit 10.2 for specific definitions of "good reason" and "cause."
- Assess the impact of these agreements on the company's cash reserves in the event of a change in control or executive departure.
- Confirm if any other executive compensation plans were amended simultaneously.